Drug Topics
JUNE 30, 2024
High-volume pharmacy fulfillment requires addressing unique factors like demand profiles, prescription throughput, and specialized processing to design a solution to address your specific needs and growth goals. This article covers steps for designing fulfillment solutions, including assessing demand, choosing appropriate automation technologies, and addressing conveyance, packaging, and sortation needs.
STAT
JUNE 30, 2024
The National Academies of Sciences, Engineering, and Medicine recently released a congressionally mandated report on how to make amyotrophic lateral sclerosis — a brutal, always fatal condition — a “livable” disease in the next 10 years. Essentially, the committee was tasked with delivering a plan for a moonshot. As a health care innovation expert and someone living with ALS, I have to say that the report barely gets off the ground.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JUNE 30, 2024
In case you missed it, this week we had news about mosquito-associated health risks, the link between cannabis and COVID-19, user experience in continuous glucose monitoring, and more.
Fierce Healthcare
JUNE 30, 2024
As Walmart shutters its primary care clinics, the retail giant inked a deal to sell its MeMD telehealth business to healthcare technology startup Fabric. | The deal will significantly expand Fabric's reach in the employer market as MeMD provides virtual care services to 30,000 employers and 5 million employees.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
JUNE 30, 2024
A few years ago, the Centers for Medicare and Medicaid Services launched a big experiment. The agency wanted to see if financial incentives and penalties would improve care for people with end-stage kidney disease. So far, it hasn’t worked, a new study finds. The End-Stage Renal Disease Treatment Choices (ETC) model is a historic effort, both because it’s the largest such experiment in the history of American health care and because, unlike previous CMS Innovation Center pilot prog
Pharmacy Times
JUNE 30, 2024
Pharmacists can also play a role in SDOH by replacing drug delivery with something else, such as food or transportation delivery, according to speakers at the ATOPP conference.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
JUNE 30, 2024
Catch up on important continuous glucose monitoring (CGM) news from the month of June.
pharmaphorum
JUNE 30, 2024
After FDA rejection last year, ARS Pharma closes on EU approval for intranasal epinephrine product for anaphylaxis
The FDA Law Blog
JUNE 30, 2024
RAPS Convergence 2024 is set to host a must-attend session on CDRH’s Total Product Life Cycle Advisory Program (TAP), promising attendees an exclusive insight into a pioneering initiative aimed at improving the medical device commercialization landscape. Session Details: A Path to Faster Breakthrough Device Commercialization – CDRH’s Total Product Life Cycle Advisory Program (TAP) Thursday, September 19, 2024, 4:30 PM – 5:30 PM Session Leader: Adrienne Lenz, RAC – Principal Medical Device Regula
BioPharm
JUNE 30, 2024
Webinar Date/Time: Wed, Jul 24, 2024 12:00 PM EDT
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Expert insights. Personalized for you.
98 
Let's personalize your content